Endometrial Cancer

Latest News

Dostarlimab plus chemotherapy appears to improve progression-free survival vs placebo plus chemotherapy in patients with recurrent endometrial cancer in the phase 3 RUBY trial.
RUBY Trial Supports Addition of Dostarlimab to Chemo as SOC in Endometrial Cancer

March 28th 2023

Dostarlimab plus chemotherapy appears to improve progression-free survival vs placebo plus chemotherapy in patients with recurrent endometrial cancer in the phase 3 RUBY trial.

Pembrolizumab Combo Yields Benefits in pMMR/dMMR Advanced Endometrial Cancer | Image Credit: © freshidea - stock.adobe.com.
Pembrolizumab Combo Yields Benefits in pMMR/dMMR Advanced Endometrial Cancer

March 28th 2023

Adavosertib does not appear to be well tolerated in patients with previously treated recurrent or persistent uterine serous carcinoma in the phase 2b ADAGIO trial.
Adavosertib Yields Clinical Activity in Uterine Serous Carcinoma

March 28th 2023

The phase 3 RUBY trial of dostarlimab plus carboplatin and paclitaxel significantly improved progression-free survival in patients with dMMR/MSI-H or MMRp/MSS endometrial cancer.
Dostarlimab Combo Yields Significant PFS in dMMR/MSI-H Endometrial Cancer

March 28th 2023

Lenvatinib Combo Yields Robust, Enduring Responses in Endometrial Cancer | Image Credit: © freshidea - stock.adobe.com.
Lenvatinib Combo Yields Robust, Enduring Responses in Endometrial Cancer

March 27th 2023

Video Interviews
Podcasts

More News